Biotech moves 50–200% on a single headline.FuzeBio shows you which one matters.
Clinical trials. FDA decisions. Pipeline breakthroughs. Our AI agents pull live data and translate complex drug science into clear investment signals.
Try a popular ticker
Institutional-grade research,
decoded for retail.
Know what it's actually worth.
Drug-by-drug rNPV and DCF models built in seconds. Adjust probability of success, peak sales, and discount rates — watch the fair value update live.
- Bull, Base, Bear scenarios
- Adjustable for your own assumptions
- Full methodology, no black box
Every drug, every stage.
Visualize the entire development pipeline at a glance — preclinical through approval — with key catalysts and timelines for each candidate.
- Phase 1 / 2 / 3 / Approved tracking
- Upcoming catalysts highlighted
Understand the science.
Detailed analysis on individual drugs — competitive positioning, key differentiators, clinical efficacy — and what each detail means for the investment thesis.
- Competitive advantage analysis
- Plain-English explanations
Map the indication.
Explore the competitive landscape for any disease. Market size, growth projections, treatment segments, and every company developing therapies.
- Total addressable market data
- Competitive landscape mapping
And more.
Catalyst calendars, competitor analysis, financial snapshots, bull & bear cases — everything you need to make informed decisions.
Start Free TrialSmart money is moving to biotech.
Average return on positive Phase 3 readout
of hedge funds hold biotech exposure
Pharma M&A war chest for buyouts
While everyone chases the same AI stocks, biotech offers asymmetric returns tech can't match. A single FDA approval can 2–3× a stock overnight. The catch? Understanding the science. That's where we come in.
Your AI research team.No PhD required.
Whether you're new to biotech or a seasoned investor, our agents handle the complexity so you can focus on decisions.
Translates the Science
You don't need to understand mRNA vs CRISPR. Our AI reads the papers and tells you what matters for the stock.
SEC, ClinicalTrials.gov, PubMed, FDA
Calculates Fair Value
What's the stock actually worth? Wall Street-grade valuation models and the methodology to back them up.
rNPV, DCF, comparables
Finds the Catalysts
Know which events could move the stock 50%+ and when they're happening. Never be blindsided by a 'surprise' FDA decision again.
PDUFA, AdCom, readouts, earnings
Gives You the Playbook
Clear bull and bear cases with price targets. Know exactly what needs to go right — and what could go wrong.
Probability-weighted scenarios
Everything you need to decide.
Stop juggling seven browser tabs. Complete biotech research in one place.
AI-Powered Price Targets
Real-time valuation using rNPV, DCF, and comparables. Adjust peak sales, probability of success, and discount rates — and watch the price target update instantly.
Bull & Bear Cases
Clear thesis statements for both sides of the trade, so you know the risks.
Catalyst Calendar
Upcoming FDA dates, trial readouts, and earnings — never miss a market-moving event.
Pipeline Analysis
Every drug candidate, trial phase, and target indication mapped clearly.
Competitive Landscape
See who else targets the same indications and how they stack up.
Financial Snapshot
Cash runway, burn rate, key metrics — know if they can fund their trials.
You already know biotech. Here's why this saves you four hours.
If you're tracking PDUFA dates and parsing trial endpoints, you don't need the basics — you need speed.
- Drug-by-drug rNPV with adjustable PoS and peak sales
- Sum-of-parts waterfalls updated in real time
- Sensitivity matrices across discount rates and PoS
- Everything you’d pull manually, synthesized in seconds
The alternative isn't cheap.
| Capability | FuzeBio$29/mo | Seeking Alpha$199/yr | Bloomberg$25k/yr | ChatGPT$20/mo |
|---|---|---|---|---|
Adjustable rNPV/DCF Models Drug-by-drug models with adjustable PoS, peak sales, discount rates | ||||
Plain English + Full Methodology Complex trial data explained clearly, with links to sources | ||||
Real-Time SEC, FDA, Clinical Data Live feeds from EDGAR, ClinicalTrials.gov, FDA databases | ||||
Hours of Research → Seconds Bull/bear cases, catalyst calendars, pipeline views — instantly | ||||
Biotech-Specific UI Built specifically for the biotech research workflow | ||||
Affordable Pricing $29/mo vs. $25k/year for Bloomberg |
Adjustable rNPV/DCF Models
Drug-by-drug models with adjustable PoS, peak sales, discount rates
Plain English + Full Methodology
Complex trial data explained clearly, with links to sources
Real-Time SEC, FDA, Clinical Data
Live feeds from EDGAR, ClinicalTrials.gov, FDA databases
Hours of Research → Seconds
Bull/bear cases, catalyst calendars, pipeline views — instantly
Biotech-Specific UI
Built specifically for the biotech research workflow
Affordable Pricing
$29/mo vs. $25k/year for Bloomberg
Biotech doesn't have to be complicated.
Start researching stocks in 30 seconds. No credit card. No PhD.
Start Free Trial